Avenacy Announces Launch of Ready-to-Use Tranexamic Acid in 0.7% Sodium Chloride Injection in the U.S. Market

Key Takeaways

• Ready‑to‑use tranexamic acid reduces preparation time in hospitals
• Avenacy's launch marks its 27th product since October 2023
• $15 million of U.S. tranexamic acid sales come from ready‑to‑use formats
• Product targets hemophilia patients undergoing tooth extraction, limiting hemorrhage

Pulse Analysis

Tranexamic acid has become a staple in managing peri‑operative bleeding, especially for patients with hemophilia undergoing dental procedures. In the United States, total sales of tranexamic acid injections reached roughly $30.2 million in the twelve months ending March 2026, with half of that revenue generated by ready‑to‑use presentations. This reflects a broader industry shift toward pre‑filled, single‑dose formats that simplify inventory management and reduce waste, a trend that aligns with hospitals’ focus on cost containment and patient safety.

Avenacy’s new 0.7 % Sodium Chloride Injection leverages that momentum by offering a pre‑filled, ready‑to‑use vial that eliminates the need for on‑site reconstitution. The streamlined workflow shortens preparation time, minimizes handling errors, and supports accurate dosing—critical factors in high‑acuity settings such as acute‑care hospitals and outpatient clinics. Moreover, the company’s differentiated packaging and labeling further mitigate selection mistakes, reinforcing its value proposition as a reliable partner for essential injectable therapies.

Since its launch in late 2023, Avenacy has rapidly expanded its portfolio, now counting 27 FDA‑approved injectable products. This aggressive growth underscores the firm’s strategy to build a resilient, diversified lineup that can adapt to evolving supply‑chain dynamics. By targeting niche, high‑need therapeutic areas and emphasizing ready‑to‑use formats, Avenacy positions itself to capture additional market share and attract wholesale partners seeking dependable, safety‑focused solutions. The launch signals continued consolidation in the specialty pharma space, where speed, reliability, and patient‑centric design are becoming decisive competitive advantages.